Treatments:Cancer
From Proteopedia
(Difference between revisions)
| Line 51: | Line 51: | ||
* [[Tasigna]] - Generic: [[Nilotinib]] | * [[Tasigna]] - Generic: [[Nilotinib]] | ||
* [[Ibrutinib]] - brand name: [[Imbruvica]] | * [[Ibrutinib]] - brand name: [[Imbruvica]] | ||
| - | See [[Treatment of chronic myelogenous leukemia]] and [[Treatment of gastrointestinal stromal | + | See [[Treatment of chronic myelogenous leukemia]] and [[Treatment of gastrointestinal stromal tumor]] |
=====[[Vascular Endothelial Growth Factor]] Inhibitor===== | =====[[Vascular Endothelial Growth Factor]] Inhibitor===== | ||
* [[Avastin]] - Generic: [[Bevacizumab]] | * [[Avastin]] - Generic: [[Bevacizumab]] | ||
Revision as of 09:14, 8 January 2025
Anti-CD20 Monoclonal Antibody
Anti-melanoma Monoclonal Antibody
Anti-prostate cancer
Anti-myeloma
Anti-acute lymphocytic leukemia
Anti-non-small cell lung cacinoma
B-Raf Kinase Inhibitor
ChemotherapyDihydrofolate Reductase Inhibitor
Epidermal Growth Factor Receptor Inhibitors
Estrogen Receptor Modulator
mTOR inhibitor
Multiple Receptor Tyrosine kinase (VEGFR, PDGFR, EGFR, KIT, Abl, RAF kinase) Inhibitors
See Treatment of chronic myelogenous leukemia and Treatment of gastrointestinal stromal tumor Vascular Endothelial Growth Factor Inhibitor
Poly ADP ribose polymerase (PARP) inhibitorsCyclin-dependent kinases inhibitors
See also Anti-cancer drugs, Anticancer drugs and RAF kinase inhibitors |
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Michal Harel, Alexander Berchansky, Karsten Theis
